---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-053745"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:37:23.552509+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics files preliminary S-1 for resale of shares under Equity Purchase Agreement with Square Gate Capital

## Summary
- Entered Equity Purchase Agreement and Registration Rights Agreement with Square Gate Capital Master Fund on Feb 20, 2025.
- Filed preliminary S-1 with SEC on April 4, 2025 for resale of Commitment Shares and future issuances.
- SEC letter on April 8, 2025 confirmed it will not review the registration statement.
- Company will request SEC accelerate effectiveness to on or about April 16, 2025.
- Final prospectus to be filed under Rule 424(b)(3) promptly after effectiveness.

## SEC filing metadata
- accession: 0000950170-25-053745
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.1, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025053745/0000950170-25-053745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025053745/hcwb-20250414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-053745
- JSON: https://secwatch.observer/filing/0000950170-25-053745.json
- Plain text: https://secwatch.observer/filing/0000950170-25-053745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.